About Jiangsu Aidea Pharmaceutical Company

The company was founded in 2009 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2020. The company takes anti-AIDS drugs as its core development field, and at the same time leverages its competitive advantage in the field of human protein, and actively explores, develops and sells innovative drugs guided by unmet domestic clinical diagnosis and treatment needs. The main business focuses on anti-HIV and human protein fields. The company's main products are crude urokinase products, crude urastatin products, new HIV drugs (enovirin tablets), new HIV drugs (enomide tablets), senna granules, and Bacillus cereus tablets. Corporate honors: It won the title of “2019-2020 Yangzhou Civilized Unit”, the crude product of human urinary kinin peptide enzyme was certified as a high-tech product in Jiangsu Province in 2014, and the first-class anti-AIDS drug ACC007 was included in the “Major New Drug Creation” science and technology project of the 13th Five-Year Plan.